Crinetics Pharmaceuticals, Inc. (CRNX)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch CRNX
See up to 3 months of CRNX. The 7-day demo opens the 1M and 3M ranges and puts CRNX on your watchlist.
Start 7-day demoLatest CRNX insider trades
Coelho Rogerio Vivaldi - DirectorOpen-market sale$120K- Stephanie Okey - DirectorOpen-market sale$224K
About Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. files with the SEC under CIK 0001658247 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
CRNX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 471 | |
| Option exercise | 8 | 39,856 | |
| Derivative transaction | 102 | 5,565,403 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CRNX insider transactions (Form 4)
4048 Form 4 filings on record, the earliest from Oct 7, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Richard Scott Struthers - Officer | Grant or award | Common Stock | 62,000 | $0.00 footnote F1 | - | |
| Richard Scott Struthers - Officer | Grant or award | Stock Option (Right to Buy) | 228,000 | $0.00 | - | |
| ||||||
 Tobin Schilke - Officer | Grant or award | Common Stock | 32,000 | $0.00 footnote F1 | - | |
| Tobin Schilke - Officer | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| ||||||
| Jeff E. Knight - Officer | Grant or award | Common Stock | 34,000 | $0.00 footnote F1 | - | |
| Jeff E. Knight - Officer | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| ||||||
| Stephen F. Betz - Officer | Grant or award | Common Stock | 30,000 | $0.00 footnote F1 | - | |
| Stephen F. Betz - Officer | Grant or award | Stock Option (Right to Buy) | 47,000 | $0.00 | - | |
| ||||||
| Isabel Kalofonos - Officer | Grant or award | Common Stock | 34,000 | $0.00 footnote F1 | - | |
| Isabel Kalofonos - Officer | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| ||||||
| Dana Pizzuti - Officer | Option exercise | Common Stock | 5,000 | $16.89 | $84K | |
| Dana Pizzuti - Officer | Open-market sale | Common Stock | 5,000 | $45.02 footnote F3 | $225K | |
| Dana Pizzuti - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| ||||||
| Dana Pizzuti - Officer | Option exercise | Common Stock | 5,000 | $16.89 | $84K | |
| Dana Pizzuti - Officer | Open-market sale | Common Stock | 4,900 | $42.65 footnote F2 | $209K | |
| Dana Pizzuti - Officer | Open-market sale | Common Stock | 100 | $43.27 footnote F3 | $4K | |
| Dana Pizzuti - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| ||||||
| Dana Pizzuti - Officer | Option exercise | Common Stock | 5,000 | $16.89 | $84K | |
| Dana Pizzuti - Officer | Open-market sale | Common Stock | 5,000 | $41.81 footnote F3 | $209K | |
| Dana Pizzuti - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| ||||||
| Richard Scott Struthers - Officer | Open-market sale | Common Stock | 4,000 | $45.00 | $180K | |
| Matthew K. Fust - Director | Option exercise | Common Stock | 10,000 | $1.91 | $19K | |
| Matthew K. Fust - Director | Open-market sale | Common Stock | 16,000 | $44.75 | $716K | |
| Matthew K. Fust - Director | Option exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Dana Pizzuti - Officer | Option exercise | Common Stock | 5,000 | $16.89 | $84K | |
| Dana Pizzuti - Officer | Open-market sale | Common Stock | 5,000 | $32.10 | $161K | |
| Dana Pizzuti - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| Dana Pizzuti - Officer | Option exercise | Common Stock | 30,000 | $16.89 | $507K | |
| Dana Pizzuti - Officer | Open-market sale | Common Stock | 30,000 | $30.43 | $913K | |
| Dana Pizzuti - Officer | Option exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Dana Pizzuti - Officer | Open-market sale | Common Stock | 6,492 | $29.18 | $189K | |
 Wendall Wierenga | Grant or award | Common Stock | 6,900 | $0.00 | - | |
| Wendall Wierenga | Grant or award | Stock Option (right to buy) | 10,350 | $0.00 | - | |
| Stephen F. Betz - Officer | Option exercise | Common Stock | 2,331 | $1.91 | $4K | |
| Stephen F. Betz - Officer | Option exercise | Stock Option (Right to Buy) | 2,331 | $0.00 | - | |
| Richard Scott Struthers - Officer | Open-market sale | Common Stock | 10,000 | $57.57 | $576K | |
| Jeff E. Knight - Officer | Open-market sale | Common Stock | 501 | $56.52 | $28K | |
| Dana Pizzuti - Officer | Option exercise | Common Stock | 14,375 | $16.89 | $243K | |
| Dana Pizzuti - Officer | Open-market sale | Common Stock | 14,375 | $54.63 | $785K | |
| Dana Pizzuti - Officer | Option exercise | Stock option (Right to Buy) | 14,375 | $0.00 | - | |
Item 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
Item 5.07, 9.01
Item 8.01
Item 8.01
Recent CRNX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
Stock trades in CRNX disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Gilbert Ray Cisneros, Jr.Democrat, CA-31 | Sale |
CRNX insider trading FAQ
What is the latest insider trade for CRNX?
Crinetics Pharmaceuticals, Inc. (CRNX) had 13 insider filings in the last 90 days, with the most recent on 2026-09-01. The full record for CRNX runs to 48 Form 4 filings, the earliest from 2024-10-07. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CRNX stock?
No insider purchases of CRNX were filed in the last 90 days.
How many insiders are selling CRNX stock?
No insider sales of CRNX were filed in the last 90 days. 26 sales are on record for this company.
Where can I see CRNX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CRNX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Wendell Wierenga view on EDGAR
- - Coelho Rogerio Vivaldi view on EDGAR
- - Stephanie Okey view on EDGAR
- - Weston Nichols view on EDGAR
- - Matthew K. Fust view on EDGAR
- - Caren Deardorf view on EDGAR
- - Camille L. Bedrosian view on EDGAR
- - Isabel Kalofonos view on EDGAR
- - Stephen F. Betz view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where CRNX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CRNX with a 7-day demo
- CRNX on your watchlist
- Every CRNX Form 4 filing on record
- Up to 3 months of CRNX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
